Literature DB >> 7629749

The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs.

T G Burke, C B Munshi, Z Mi, Y Jiang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7629749     DOI： 10.1002/jps.2600840426

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  12 in total

1.  Metabolic pathways of the camptothecin analog AR-67.

Authors:  Jamie Horn; Marta Milewska; Susanne M Arnold; Markos Leggas
Journal:  Drug Metab Dispos       Date:  2010-12-28       Impact factor: 3.922

2.  Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies.

Authors:  Eric X Chen; Gerald Batist; Lillian L Siu; Naeema Bangash; Martha Maclean; Lynn McIntosh; Wilson H Miller; Amit M Oza; Chetan Lathia; Oana Petrenciuc; Lesley Seymour
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

3.  Tumor physiology and charge dynamics of anticancer drugs: implications for camptothecin-based drug development.

Authors:  D J Adams; L R Morgan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 4.  Clinical pharmacokinetics of topotecan.

Authors:  V M Herben; W W ten Bokkel Huinink; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 5.  Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation.

Authors:  Anil Kumar; Fei Chen; Anbu Mozhi; Xu Zhang; Yuanyuan Zhao; Xiangdong Xue; Yanli Hao; Xiaoning Zhang; Paul C Wang; Xing-Jie Liang
Journal:  Nanoscale       Date:  2013-09-21       Impact factor: 7.790

Review 6.  Topotecan. A review of its potential in advanced ovarian cancer.

Authors:  R N Brogden; L R Wiseman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

7.  Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.

Authors:  Stuart A Grossman; Kathryn A Carson; Surasak Phuphanich; Tracy Batchelor; David Peereboom; L Burt Nabors; Glenn Lesser; Fredrick Hausheer; Jeffrey G Supko
Journal:  Neuro Oncol       Date:  2008-06-24       Impact factor: 12.300

8.  Triazene drug metabolites: part 15. Synthesis and plasma hydrolysis of anticancer triazenes containing amino acid carriers.

Authors:  E Carvalho; J Iley; M J Perry; E Rosa
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

9.  Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice.

Authors:  William C Zamboni; Laura L Jung; Sandra Strychor; Erin Joseph; Beth A Zamboni; Sarah A Fetterman; Brian J Sidone; Thomas G Burke; Dennis P Curran; Julie L Eiseman
Journal:  Invest New Drugs       Date:  2008-02-02       Impact factor: 3.850

Review 10.  Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity.

Authors:  R E Parchment
Journal:  Environ Health Perspect       Date:  1998-04       Impact factor: 9.031
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.